Based on this observation we hypothesize that because the anti-IL-23 treatment started after 8 weeks of HFD, WT mice had reached a level of inflammation and IL-23 activation sufficient to induce significant NAFLD damage. The gene discussed is IL23A; the disease is metabolic dysfunction-associated steatotic liver disease.